Torley Helen 4

What Happened
Helen Torley, President & CEO and a director of Halozyme Therapeutics (HALO), had restricted stock units (RSUs) and performance stock units (PSUs) vest and settle on 2026-02-16, resulting in the issuance/conversion of 89,055 shares. To cover tax withholding obligations, the issuer withheld 48,043 of those shares (treated as dispositions) at $79.44 per share, generating tax-withholding value of $3,816,536. The underlying awards show a $0 exercise price consistent with RSU/PSU settlement; the net number of shares retained by Torley after withholding is approximately 41,012.

Key Details

• Transaction date: 2026-02-16; Form 4 filed 2026-02-17 (appears timely).
• Awards vested/converted: 89,055 shares total (21,009; 16,875; 51,171 in separate award tranches).
• Shares withheld for taxes: 48,043 shares (11,334; 9,104; 27,605) at $79.44 each; total value ≈ $3,816,536.
• Net shares retained after withholding: ~41,012.
• Footnotes: F4 = vesting/settlement of restricted stock units; F5 = vesting/settlement of performance stock units; F1–F3 = shares withheld by issuer to satisfy tax withholding.
• No open-market sale reported — withholding is an internal share-for-tax arrangement, not a market sale.

Context

• This was a settlement of award units (not a market purchase or a voluntary sale). The $0.00 exercise price entries reflect RSU/PSU settlement rather than option exercise requiring cash.
• Share withholding to cover taxes is common and does not necessarily indicate buying/selling sentiment by the insider.
• The filing does not report total shares owned post-transaction beyond the net retained from this vesting; check company filings for up-to-date beneficial ownership if needed.